Publications by authors named "Jeff Loutit"

Claim this Profile
T
The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant .
Olga Lomovskaya, Debora Rubio-Aparicio, Ruslan Tsivkovski, Jeff Loutit, Michael Dudley

Antimicrob Agents Chemother· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.
Mark Redell, Greg Moeck, Christopher Lucasti, Stephanie Durso, Cynthia Kennedy, Jeff Loutit

Open Forum Infect Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potency of Meropenem-Vaborbactam in Lung Surfactant.
Debora Rubio-Aparicio, Jeff Loutit, Michael Dudley, Olga Lomovskaya

Antimicrob Agents Chemother· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aerosol antibiotics: considerations in pharmacological and clinical evaluation.
Michael N Dudley, Jeff Loutit, David C Griffith

Curr Opin Biotechnol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
David S Alberts, Christian Marth, Ronald D Alvarez, Gary Johnson, Mariusz Bidzinski, Jeff Loutit

Gynecol Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis